A pioneering new "smart drug" is demonstrating remarkable potential in cancer treatment by effectively removing the "invisibility cloak" that often shields cancer cells from conventional therapies. This experimental drug, known as GRWD5769, works by preventing cancer cells from hiding from the immune system, thereby allowing immunotherapy treatments to more effectively identify and destroy disease cells. Early results from a phase 1 trial indicate that GRWD5769 can shrink tumours by at least 30% in six of the world’s most common forms of the disease, offering new hope for patients who have exhausted other treatment options.

The innovative mechanism of GRWD5769 targets an enzyme called ERAP1 (endoplasmic reticulum aminopeptidase 1). Cancer cells often manipulate ERAP1 to evade the immune system, making them invisible to the body's T-cells, which are crucial for attacking infections and diseases. By inhibiting ERAP1, GRWD5769 essentially removes this invisibility cloak, exposing the tumour cells and rendering them vulnerable to existing immunotherapy treatments like cemiplimab.

The trial, which spanned the UK, France, Spain, and Australia, involved 83 patients diagnosed with cervical, bladder, liver, bowel, lung, or head and neck cancers. A critical aspect of the study was its focus on patients who had previously failed to respond to treatment, with most having no remaining options after their immunotherapy had stalled or ceased to be effective. The trial was led by the Christie NHS foundation trust in Manchester, England, with the drug itself developed by Oxford-based Greywolf Therapeutics.

The findings, presented at the American Society of Clinical Oncology’s annual meeting in Chicago, revealed significant efficacy. Tumours shrank in 26 of the 83 patients, with 15 experiencing reductions of at least 30%. Furthermore, GRWD5769 was shown to halt the progression of the disease for at least six months in a notable percentage of patients across various cancer types: 18% of cervical cancer patients, 32% of liver cancer patients, 36% of bladder cancer patients, 38% of those with head and neck cancer, and more than half of bowel (51%) and lung (55%) cancer patients.

Among the first to benefit from this breakthrough is Pat Brogan, a 68-year-old from Cowdenbeath, Scotland, who was diagnosed with stage four lung cancer in 2021. After undergoing chemotherapy and immunotherapy for about three years, his tumours began to grow again. He joined the trial, and his tumours have since shrunk by almost a third. This remarkable turnaround has allowed him to look forward to walking his daughter down the aisle and planning a holiday to Spain with his wife, milestones he once thought unattainable. Brogan described the treatment as having